ADVFN - Advanced Financial Network.
HOME» NYSE » M » MDT Stock Price » MDT Stock News

Medtronic Share News

 Medtronic, Inc. Stock Price
MDT Stock Price
 Medtronic, Inc. Stock Chart
MDT Stock Chart
 Medtronic, Inc. Stock News
MDT Stock News
 Medtronic, Inc. Company Information
MDT Company Information
 Medtronic, Inc. Stock Trades
MDT Stock Trades

St. Jude Seeks Retraction Of Riata Study

DOW JONES NEWSWIRES St. Jude Medical Inc. (STJ) said it is seeking a retraction of a study published in a medical journal last month that found heart-defibrillator wires made by the company were responsible for at least 20 deaths, citing inaccurate facts and biased analysis. In the Heart Rhythm Journal last month, prominent cardiologist Robert G. Hauser wrote that separate Riata leads, used in the company's implantable defibrillators, are responsible for the deaths because of "high-voltage failures." Hauser said the deaths allegedly caused by Riata malfunctions were about nine times greater than a competing lead called the Quattro Secure made by Medtronic Inc. (MDT). The medical device company had previously said Hauser's article contains several errors and argued that the Quattro Secure contains different materials from those of Riata. On Friday, St. Jude said Hauser's research substantially undercounted total deaths on the U.S. Food and Drug Administration's device database, called MAUDE, for Quattro Secure, which resulted in errors comparing Riata leads to the Quattro Secure lead. The company said its independent search of the MAUDE database found 377 reports of deaths involving Quattro Secure leads, while Hauser reported 62. The company's analysis of Riata lead events in the database found 74 deaths, while Hauser reported 71. St. Jude also said Hauser's analysis of "lead-related" deaths is biased against companies that are more transparent in reporting on device malfunctions and said its comparison of Riata leads to Quattro Secure is "flawed," given the devices' different materials. St. Jude also said the method of the study, using MAUDE reports to compare devices, "is not appropriate," noting the FDA site says the data are "not intended to be used either to evaluate rates of adverse events or to compare adverse event occurrence rates across devices." Hauser wasn't immediately available to respond to a call for comment. The Riata leads are no longer on the market but are still implanted in about 128,000 patients world-wide. The U.S. Food and Drug Administration has termed the defibrillator issues a Class I recall, which applies to grave dangers like chance of death. On Wednesday, St. Jude said that it would stop selling its QuickSite and QuickFlex left-ventricular leads used to connect cardiac resynchronization therapy devices to the heart, following reports of wires wearing through their silicone covering. Cardiac resynchronization therapy devices are used to help the heart beat more efficiently, while defibrillators are designed to deliver life-saving shocks when needed. St. Jude shares closed at $40.97 Thursday and are up 19% since the start of the year. -By Nathalie Tadena, Dow Jones Newswires; 212-416-3287; nathalie.tadena@dowjones.com

Stock News for Medtronic (MDT)
DateTimeHeadline
03/26/201509:16:52Lombard's Unique Stent-Graft Rapidly Penetrating Endovascular...
03/25/201517:04:25Amended Current Report Filing (8-k/a)
03/25/201516:00:00Medtronic Highlights New Data in JAMA Surgery Demonstrating Significant...
03/24/201506:33:37Medtronic Files 8K - Regulation FD
03/20/201518:43:04Statement of Changes in Beneficial Ownership (4)
03/20/201509:00:00Next Week In Biotech: Pediatric Safety Ad Comm, BIO Asia, Sinovac...
03/18/201508:33:32'New' Medtronic Significantly Undervalued After Merger With Covidien
03/17/201520:41:39Dividend Growth Checkup - Part II
03/17/201515:36:42Statement of Changes in Beneficial Ownership (4)
03/16/201517:39:12Why Edwards Lifesciences Sky-Rocketed Today
03/16/201511:00:26Medtronic Seeks Runners with Medical Technology for 2015 "Global...
03/16/201507:44:56Two-year data show Medtronic CoreValve TAVR patients do better...
03/15/201513:45:27Medtronic CoreValve® System Sustains Superior Survival Benefit...
03/14/201518:45:35Medtronic to Initiate Clinical Study of Drug-Filled Stent Following...
03/14/201515:00:22Medtronic CoreValve® Evolut(TM) R System Yields Exceptional...
03/12/201509:30:32Medtronic Initiates Pivotal Studies of Resolute Onyx(TM) Drug-Eluting...
03/09/201518:45:33Why Medtronic-Covidien Deal Will Lead To Strong 2015 Performance
03/03/201518:07:15NuVasive: Court Overturns $102 Million Award to Medtronic--Update
03/03/201517:44:58NuVasive: Court Overturns $102 Million Award to Medtronic
03/03/201516:00:43Medtronic EVP & CFO Gary Ellis to Speak at Barclays Healthcare...

Medtronic and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad